Drug
Erenumab Dose 1
Erenumab Dose 1: highest development phase Phase 3, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Erenumab Dose 1 NCT03832998 | Phase 3 | Migraine |
Latest
No recent events.
Follow Erenumab Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.